<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25068" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methamphetamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yasaei</surname>
            <given-names>Rama</given-names>
          </name>
          <aff>UCLA Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rama Yasaei declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25068.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Methamphetamine is one of the powerful stimulants of the central nervous system (CNS). It is sometimes a second-line treatment for attention deficit hyperactivity disorder and obesity; however, methamphetamine is better known as a recreational drug. This activity will highlight the mechanism of action, adverse event profile/toxicity, pharmacology, monitoring, relevant interactions, and street names of methamphetamine, pertinent for interprofessional team members should they encounter patients who require therapy with or have misused this drug.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of methamphetamine.</p></list-item><list-item><p>Describe the adverse effects of methamphetamine when used medically.</p></list-item><list-item><p>Summarize the toxicity of methamphetamine.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who either are or have previously misused methamphetamine or who may require it therapeutically.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25068&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25068">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25068.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Methamphetamine is one of the powerful stimulants of the&#x000a0;central nervous system (CNS). It is sometimes&#x000a0;used as&#x000a0;a second-line treatment for attention deficit hyperactivity disorder and obesity; however, methamphetamine is better known as a recreational drug.</p>
        <p>Methamphetamine&#x000a0;was first discovered&#x000a0;in 1893 from two chemical subgroups: dextromethamphetamine and levomethamphetamine. After two decades, in 1919, methamphetamine originated&#x000a0;from amphetamine in Japan. Later&#x000a0;in the 1930s, the drug was introduced to the United States as a bronchial&#x000a0;inhaler and a nasal decongestant. Later, it was used to treat obesity. Overall, the term methamphetamine refers to an equal&#x000a0;mixture of&#x000a0;dextromethamphetamine and levomethamphetamine&#x000a0;in their pure amine forms.&#x000a0;Prescribing this medication is limited&#x000a0;due to its neurotoxic potential and risk of recreational use as a&#x000a0;euphoriant. Today, there are safer medications of choice with the same treatment efficacy, and hence, the use of methamphetamines in the United States is very limited.<xref ref-type="bibr" rid="article-25068.r1">[1]</xref></p>
        <p>Due to illicit trafficking and recreational use of racemic methamphetamine,&#x000a0;levomethamphetamine, and&#x000a0;dextromethamphetamine, the agent is a schedule II controlled substance in the United States and the&#x000a0;United Nations Convention on Psychotropic Substances.<xref ref-type="bibr" rid="article-25068.r2">[2]</xref></p>
        <p>Because of&#x000a0;the relatively simple&#x000a0;chemical process to synthesize methamphetamine, it can&#x000a0;be produced illicitly in meth-labs nationwide.<xref ref-type="bibr" rid="article-25068.r3">[3]</xref> Illegal laboratories and larger super-labs across the United States, particularly in California (Central Valley), Arizona, Utah, and Texas, have surfaced over the past three decades. With the growth of Mexico-based traffickers and the expansion of independent illegal labs, methamphetamine is mass manufactured in many places today in the Pacific Northwest, Midwest, and some parts of the southeast and the northeast United States.<xref ref-type="bibr" rid="article-25068.r3">[3]</xref></p>
        <p>The use of methamphetamine triggers elevated mood, alertness, increase concentration, energy, decreased appetite, and causes weight loss and increased sexual libido (recreational methamphetamine).</p>
        <p>The use of methamphetamine in higher doses can induce psychosis, bleeding in the brain, skeletal muscle breakdown, and seizures. Moreover, it can cause violent behavior, mood swings, and psychosis such as paranoia, delirium, auditory and visual hallucination, and delusions when used chronically.</p>
        <p>Chronic long-term methamphetamine use can be highly addictive, and if it is discontinued abruptly, it might lead to withdrawal symptoms that can be persistent for months after use.</p>
        <p>
<bold>Street Terms for Methamphetamine</bold>
</p>
        <p>Meth, crystal meth, crystal, speed, scootie, yellow powder, crank, ice, spoosh, glass, chalk, redneck cocaine, yellow barn, tina, tick-tick</p>
        <p>
<bold>Street Terms for&#x000a0;</bold>
<bold>Smokable</bold>
<bold>&#x000a0;Methamphetamine</bold>
</p>
        <p>Hot ice, L.A. glass, hiropon, super Ice, L.A. ice, Batu, quartz,&#x000a0;hanyak<xref ref-type="bibr" rid="article-25068.r1">[1]</xref></p>
      </sec>
      <sec id="article-25068.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Methamphetamine affects the central nervous system (CNS)&#x000a0; by enhancing the release of monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine.<xref ref-type="bibr" rid="article-25068.r4">[4]</xref>&#x000a0;The use of methamphetamine can lead to many pharmacological effects because of its ability to use various molecular processes. Methamphetamine causes the levels of monoamines to be increased by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Discharging the monoamines out of their storage and freeing them into the synaptic space by making reversal action of the dopamine transporters</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obstructing the reuptake of monoamines by preventing the activity of transporters of monoamine[6]</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Methamphetamine can increase the expression of CRE-Luc by TAAR1 in transfected cells. Methamphetamine interacts with TAAR1, which triggers a definite inhibition in dopamine uptake dependent on TAAR1 in transfected cells. Methamphetamine has a similar effect on brain striatal synaptosomes.<xref ref-type="bibr" rid="article-25068.r5">[5]</xref><xref ref-type="bibr" rid="article-25068.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reducing the dopamine transporters expressions at the cell surface</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The proliferation of the cytosolic levels of monoamines by inhibiting the monoamine oxidase activity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enhancing the expression and activity of the dopamine-synthesizing&#x000a0;enzyme tyrosine&#x000a0;hydroxylase<xref ref-type="bibr" rid="article-25068.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Methamphetamine is highly lipid-soluble, which helps to be transferred relatively fast across the blood-brain barrier and has an immediate effect on the CNS.<xref ref-type="bibr" rid="article-25068.r2">[2]</xref></p>
      </sec>
      <sec id="article-25068.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Methamphetamine&#x000a0;can be ingested&#x000a0;orally, through intravenous injection, smoked, and snorted.</p>
      </sec>
      <sec id="article-25068.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>People who use methamphetamine feel an acute, powerful short rush for about 5 to 30 minutes, which varies based on different routes of use. The drug also causes&#x000a0;an enhanced energy level, decreases appetite, and creates euphoria for a range of 6 to 12 hours.</p>
        <p>
<bold>&#x000a0;Short-Term Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased appetite</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Increased body temperature &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Panic attack</p>
          </list-item>
          <list-item>
            <p>Mydriasis (dilation of pupils)</p>
          </list-item>
          <list-item>
            <p>Disturbed sleep patterns</p>
          </list-item>
          <list-item>
            <p>Violent, bizarre, and erratic behavior</p>
          </list-item>
          <list-item>
            <p>Hallucinations and irritability</p>
          </list-item>
          <list-item>
            <p>Seizures, convulsions, and death from high doses</p>
          </list-item>
        </list>
        <p>
<bold>Long-Term Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Long-lasting damage to the blood vessel of the heart and brain</p>
          </list-item>
          <list-item>
            <p>Lung, liver, and kidney damage</p>
          </list-item>
          <list-item>
            <p>Hypertension that can lead to heart attacks, strokes, and death</p>
          </list-item>
          <list-item>
            <p>Severe tooth degeneration</p>
          </list-item>
          <list-item>
            <p>In cases where the drug was sniffed, destruction of soft tissues in the nose</p>
          </list-item>
          <list-item>
            <p>In cases where the drug was smoked, respiratory problems</p>
          </list-item>
          <list-item>
            <p>In cases where the drug was injected, infectious diseases, cellulitis, and abscesses</p>
          </list-item>
          <list-item>
            <p>Weight loss and malnutrition</p>
          </list-item>
          <list-item>
            <p>Disorientation, apathy, confusion, and exhaustion</p>
          </list-item>
          <list-item>
            <p>Severe psychological dependence</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Damage to the brain structure similar to Alzheimer disease, epilepsy, and stroke</p>
          </list-item>
        </list>
        <p>
<bold>Tweaking</bold>
</p>
        <p>The last stage of methamphetamine misuse happens when the person who inappropriately uses methamphetamine becomes paranoid and irritable because of a lack of sleep for about 3 to 15 days. This behavior&#x000a0;is called "tweaking," and the person with this behavior&#x000a0;is&#x000a0;known&#x000a0;as the "tweaker." Usually, tweakers continue&#x000a0;to require more methamphetamine to get to the original high.<xref ref-type="bibr" rid="article-25068.r8">[8]</xref>&#x000a0;This effect is&#x000a0;difficult&#x000a0;to achieve, which causes frustration and irritability, and unsteady behavior in the tweaker. Because&#x000a0;tweakers are unpredictable, they can behave violently, can get involved in domestic arguments, spur-of-the-moment offenses, and become&#x000a0;a danger&#x000a0;to others or themselves.<xref ref-type="bibr" rid="article-25068.r9">[9]</xref> A&#x000a0;tweaker&#x000a0;can behave normally and have clear eyes, concise speech, and brisk movements;&#x000a0;however,&#x000a0;careful observation will indicate that the person's eye movement is much faster than normal (up to 10 times). They have a minor quiver voice and jerky movements.&#x000a0;Some tweakers minimize or cover these physical symptoms by using a depressant like alcohol or opioids; however, the use of a depressant by the tweaker increases his or her negative feelings of paranoia, irritability, and frustration significantly. Other people around these users should use extreme caution because of their unpredictable behaviors.<xref ref-type="bibr" rid="article-25068.r10">[10]</xref></p>
      </sec>
      <sec id="article-25068.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Having thoughts of suicide</p>
          </list-item>
          <list-item>
            <p>Tourette syndrome</p>
          </list-item>
          <list-item>
            <p>Hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Bipolar disorder</p>
          </list-item>
          <list-item>
            <p>Psychotic disorder</p>
          </list-item>
          <list-item>
            <p>Drug abuse</p>
          </list-item>
          <list-item>
            <p>Behaving with excessive cheerfulness or activity</p>
          </list-item>
          <list-item>
            <p>Chronic muscle twitches or movements</p>
          </list-item>
          <list-item>
            <p>Aggressive behavior</p>
          </list-item>
          <list-item>
            <p>Increased ophthalmic pressure</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>History of a heart attack</p>
          </list-item>
          <list-item>
            <p>Coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Arrhythmia</p>
          </list-item>
          <list-item>
            <p>Chronic heart failure</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Atherosclerosis</p>
          </list-item>
          <list-item>
            <p>Numbness</p>
          </list-item>
          <list-item>
            <p>Prickling</p>
          </list-item>
          <list-item>
            <p>Tingling of fingers and toes</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Loss of appetite</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>Breastfeeding mothers</p>
          </list-item>
          <list-item>
            <p>Increased cardiovascular event risk</p>
          </list-item>
          <list-item>
            <p>Structural disorder of the heart</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease stage 4 (severe) or 5 (failure)</p>
          </list-item>
          <list-item>
            <p>Kidney disease with a&#x000a0;likely reduction in kidney function</p>
          </list-item>
          <list-item>
            <p>Allergic reaction to sympathomimetic agents or amphetamine analogs</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25068.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Methamphetamine users have different recognizable symptoms, for example, lack of sleep (insomnia), acute anxiety, agitation, and psychotic or violent behavior. If these types of behavior develop after using the methamphetamine, the meth use may have developed dependency. Chronic meth users also usually show poor personal hygiene and sores on their bodies from picking at "crank bugs," unhealthy complexion, pallor, and tactile hallucinations that&#x000a0;often&#x000a0;occur in tweakers.&#x000a0;Methamphetamine users may develop cracked teeth because of extreme clenching of their jaw when&#x000a0;they are high on methamphetamine.</p>
      </sec>
      <sec id="article-25068.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The use of methamphetamine can&#x000a0;cause&#x000a0;physical and psychological dependence and increased tolerance. Because of the rapid development of tolerance, methamphetamine users frequently need to increase the dose to get to the satisfying "high," which can be very&#x000a0;dangerous because the administration of too much methamphetamine also increases the risk of an overdose.<xref ref-type="bibr" rid="article-25068.r11">[11]</xref>&#x000a0;Based on the reports from 2011, more than 102,000 emergency department visits in the United States were related to methamphetamine use, with over 50% of users also using a combination of other drugs such as alcohol and marijuana, thus producing a synergistic effect. Knowing the physical and behavioral symptoms of the methamphetamine overdose and diagnosis of the toxicity is&#x000a0;essential&#x000a0;for saving the patient's life.<xref ref-type="bibr" rid="article-25068.r12">[12]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Acute:</italic>&#x000a0;When methamphetamine users experience an adverse reaction due to&#x000a0;using a large amount of methamphetamine one time, it can be fatal.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Chronic:&#x000a0;</italic>Result of many adverse health effects of chronic methamphetamine abuse</p>
          </list-item>
        </list>
        <p>Signs and symptoms of methamphetamine toxicity:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mydriasis (dilated pupils)</p>
          </list-item>
          <list-item>
            <p>Bradycardia or tachycardia</p>
          </list-item>
          <list-item>
            <p>Irregular heart rhythm (arrhythmia)</p>
          </list-item>
          <list-item>
            <p>Chest pains</p>
          </list-item>
          <list-item>
            <p>Shortness of breath</p>
          </list-item>
          <list-item>
            <p>Increased body temperature</p>
          </list-item>
          <list-item>
            <p>Heart attack</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Kidney damage</p>
          </list-item>
          <list-item>
            <p>Altered mental status.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal distress</p>
          </list-item>
          <list-item>
            <p>Agitation, violent, psychotic behaviors&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients who experience methamphetamine toxicity usually present with an altered mental status that can&#x000a0;present as psychotic episodes, irritability, suicidal ideation, and rarely coma or seizures.</p>
        <p>Some patients present with psychotic symptoms, including tactile hallucinations and severe paranoia.</p>
        <p>Chronic long-term methamphetamine use can also cause dental complications, significant weight loss, and skin problems such as sores and abscesses.<xref ref-type="bibr" rid="article-25068.r3">[3]</xref></p>
      </sec>
      <sec id="article-25068.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the unpredictable behaviors, irritability, and the possibility of psychotic behavior of methamphetamine users, especially during the hospital visit due to the overdose or complication, the safety of medical and security staff is important. Hence, the advice is always to use precautions when dealing with these patients. Another healthcare worker or security personnel should always accompany these patients. The triage nurse should be fully aware of the adverse effects of amphetamine and ensure that the emergency department is fully aware of the individual&#x000a0;admitted. This interprofessional team approach to addressing these patients should include clinicians, nurses, and pharmacists, who can collaborate and communicate across interdisciplinary lines to ensure these patients get the care they need, whether misusing the drug or in the rare instances where it has a therapeutic indication. [Level 5]</p>
      </sec>
      <sec id="article-25068.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25068&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25068">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25068/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25068">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25068.s11">
        <title>References</title>
        <ref id="article-25068.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radfar</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rawson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts.</article-title>
            <source>Addict Health</source>
            <year>2014</year>
            <season>Summer-Autumn</season>
            <volume>6</volume>
            <issue>3-4</issue>
            <fpage>146</fpage>
            <page-range>146-54</page-range>
            <pub-id pub-id-type="pmid">25984282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cisneros</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Ghorpade</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes.</article-title>
            <source>Neuropharmacology</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>85</volume>
            <fpage>499</fpage>
            <page-range>499-507</page-range>
            <pub-id pub-id-type="pmid">24950453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krasnova</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Cadet</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Methamphetamine toxicity and messengers of death.</article-title>
            <source>Brain Res Rev</source>
            <year>2009</year>
            <month>May</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>379</fpage>
            <page-range>379-407</page-range>
            <pub-id pub-id-type="pmid">19328213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Der-Ghazarian</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Charmchi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Noudali</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Holter</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Newbern</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Neisewander</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Neural Circuits Associated with 5-HT<sub>1B</sub> Receptor Agonist Inhibition of Methamphetamine Seeking in the Conditioned Place Preference Model.</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>17</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>3271</fpage>
            <page-range>3271-3283</page-range>
            <pub-id pub-id-type="pmid">31042352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Eshleman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Janowsky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Activation of Trace Amine-Associated Receptor 1 Stimulates an Antiapoptotic Signal Cascade via Extracellular Signal-Regulated Kinase 1/2.</article-title>
            <source>Mol Pharmacol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-504</page-range>
            <pub-id pub-id-type="pmid">31409621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miner</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Janowsky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>371</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-44</page-range>
            <pub-id pub-id-type="pmid">31320495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Shiue</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>In vivo long-lasting alterations of central serotonin transporter activity and associated dopamine synthesis after acute repeated administration of methamphetamine.</article-title>
            <source>EJNMMI Res</source>
            <year>2019</year>
            <month>Sep</month>
            <day>18</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <pub-id pub-id-type="pmid">31535286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauw</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meppiel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steichen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Conan</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Capron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Broucker</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Isolated persistent acute global amnesia after acute abuse of 3,4-methylenedioxy-methamphetamine (MDMA).</article-title>
            <source>J Neurol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>386</volume>
            <fpage>36</fpage>
            <page-range>36-38</page-range>
            <pub-id pub-id-type="pmid">29406963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>McCready</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Hickok</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Psychopathy and Corticostriatal Connectivity: The Link to Criminal Behavior in Methamphetamine Dependence.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">32180738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaushal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Role of sigma receptors in methamphetamine-induced neurotoxicity.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-7</page-range>
            <pub-id pub-id-type="pmid">21886562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhaom</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Factors affecting the occurrence of psychotic symptoms in chronic methamphetamine users.</article-title>
            <source>J Addict Dis</source>
            <year>2018</year>
            <season>Jul-Dec</season>
            <volume>37</volume>
            <issue>3-4</issue>
            <fpage>202</fpage>
            <page-range>202-210</page-range>
            <pub-id pub-id-type="pmid">31682200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25068.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weng</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Hwa</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of analytically confirmed illicit substance-using patients in the Emergency Department.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>1827</fpage>
            <page-range>1827-1834</page-range>
            <pub-id pub-id-type="pmid">32037264</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
